Please click on the names below for more details on each confirmed speaker:

Weill Cornell Medicine

Dr Artis completed his doctoral research training at the University of Manchester, UK focusing on regulation of immunity and inflammation in the intestine. Following receipt of a Wellcome Trust Prize Traveling Fellowship, he undertook his post-doctoral fellowship training at the University of Pennsylvania where he continued his research training in examining the regulation of immune responses at barrier surfaces. Dr Artis joined the faculty at Penn in 2005 and became a Professor of Microbiology in 2014. Dr. Artis then moved to Cornell University and became the Michael Kors Professor of Immunology, Director of the Jill Roberts Institute for IBD Research at Weill Cornell Medicine, and Director of the Friedman Center for Nutrition and Inflammation at Cornell University in New York City. Dr Artis has developed a research program focused on dissecting the pathways that regulate innate and adaptive immune cell function at barrier surfaces in the context of health and disease. His research program also encompasses a significant effort to translate research findings in pre-clinical models into patient-based studies of immune-mediated diseases. Dr Artis is funded by NIH, CCFA and BWF and has been the recipient of Young Investigator Awards from AAI, CCFA and ICIS, the Colyton Prize, the Stanley Cohen Prize and the AAI-BD Biosciences Investigator Award.

University of Birmingham

University of Pittsburgh

I am a cellular immunologist with a research focus on dissecting the role of cytokine signaling in the immunity against renal infections and pathogenesis of autoinflammatory kidney diseases. Building upon my prior work in kidney inflammatory conditions, my research program at University of Pittsburgh addresses a major problem in the field of cytokine Interleukin-17 (IL-17) in renal damage during infection and autoimmunity. The kidney is an organ particularly susceptible to damage caused by infections and autoinflammatory conditions. Even so, renal immunology remains remarkably understudied by immunologists. I have positioned myself to take advantage of this important knowledge gap. Using mouse models and human bio-specimens, we are deeply involved in understanding the mechanisms of kidney tissue damage in infections and autoimmune conditions. Recently, we also showed the mechanisms of immune dysfunction in patients with kidney disease, which leads to increased susceptibility of infection in these patients. Thus, my research embodies the features of a basic scientist with scientific contributions spanning from very basic work in cell/animal models to more clinical work in humans.

Trinity College Dublin

Andrew Bowie is Professor of Innate Immunology at Trinity College Dublin (TCD). He obtained his PhD in Biochemistry from Trinity College Dublin in 1997. After postdoctoral training with Prof Luke O’Neill, he was appointed as a lecturer UCD, before returning to TCD in 2001 to establish the first Immunology undergraduate degree in Ireland. In 2008 he was elected a Fellow of TCD, and in 2014 a member of the Royal Irish Academy. In 2017 he was awarded the Irish Society for Immunology Public Lecture Medal for his outstanding contribution to Irish Immunology. His research focuses on innate immune sensing and signalling mechanisms of pathogens, especially viruses.

The University of Cambridge

University of Oxford

Chris obtained a degree in Biochemistry from the University of Oxford (1985) with subsequent undergraduate training in Medicine (MBBS) at the Royal Free Hospital, London (1990). His postgraduate medical training was in General Medicine and Rheumatology at the Hammersmith Hospital, London and John Radcliffe Hospital, Oxford. He obtained a DPhil arising from a Wellcome Trust Clinical Training Fellowship at the Institute Molecular Medicine, Oxford in 1996.
Funded by a Wellcome Trust Clinician Scientist Fellowship, he joined the Department of Rheumatology in Birmingham later that year. In 2001 he was awarded an MRC Senior Clinical Fellowship and in 2002 became Arthritis Research UK Professor of Rheumatology
In May 2017 he took up a new joint academic post between the Universities of Birmingham and Oxford as Director of Clinical Research at the Kennedy Institute of Rheumatology Oxford and Director of NIHR Infrastructure in Birmingham for Birmingham Health Partners to Direct the Arthritis Therapy Acceleration Programme (A-TAP)

Weill Cornell Medicine

Dr. Cesarman was born in Mexico City, where she obtained her MD degree, followed by a PhD from New York University and Anatomic Pathology Residency training at the College of Physicians and Surgeons of Columbia University. Dr. Cesarman was part of the team that discovered the Kaposi’s sarcoma herpesvirus (KSHV/HHV-8) and found that this virus is consistently present in a subset of non-Hodgkin’s lymphomas, designated primary effusion lymphomas (PEL), which led to the recognition of these lymphomas as a distinct disease entity. Current research efforts in the Cesarman lab are aimed at better understanding mechanisms of herpesviral pathogenesis, including the role of herpesviruses in the tumor microenvironment, with the goal of directly therapeutically targeting viral oncogenic signals, or indirectly through immunotherapeutic approaches. Dr. Cesarman has also conducted cancer genomic studies to gain a deeper understanding of the viral and cellular contribution to the tumor genetic and epigenetic landscape, focusing on lymphoma and other AIDS-related malignancies.

Hanyang University

Dr. Je-Min Choi who is a tenured professor at Hanyang University in Korea was graduated at Department of Biotechnology, Yonsei University in Korea and completed graduate school at Yonsei for both Master and Ph.D. During his PhD, he studied CTLA-4 signaling in T cells to modulate inflammation in asthma or arthritis by utilizing cell-penetrating peptide. When he started post-doctoral training at Yale University School of Medicine, he continued immune regulation study with Foxp3 to induce Treg cells in colitis as well as investigated role of PPARs in T cells regarding Tfh/germinal center reaction and autoimmunity. His current major interests are pathogenic T cell functions in autoimmune diseases as well as development of immune modulatory molecules by targeting T cell functions.; 1) Antigen-independent bystander T cell functions in autoimmune pathogenesis, 2) Gender differences of autoimmunity and T cell functions, 3) Immune modulatory drug development by cell-penetrating peptide or proteins. 4) Autoimmune disease like multiple sclerosis, IBD, psoriasis, etc.

La Jolla Institute of Allergy and Immunology

Dr. Crotty’s lab studies the fundamental immunology underlying vaccine functions. Initially trained in molecular virology and then viral immunology, Crotty’s laboratory focuses on both the basic immunology of T follicular helper (Tfh) CD4 T cells (Science 2009, Immunity 2019), viral immunology including SARS-CoV-2 (Cell 2020), B cell immunodominance (Science 2016, Immunity 2018, Science 2019,), and the central roles of germinal centers and memory in vaccine immunology (Cell 2019, Nature Medicine 2020). Dr. Crotty was a Pew Scholar and a 2016-2019 Highly Cited Researcher. His recent COVID-19 immunology work has become the highest attention getting Cell paper ever (Cell 2020; Nature Reviews Immunology 2020). His newest study on COVID-19 immune memory (Science 2021) is the largest every study of adaptive immunity (CD4 T cells, CD8 T cells, antibodies, and memory B cells) for any viral infection, and was covered by the New York Times and other major media outlets.

University of Edinburgh, Edinburgh, UK & Institute Imagine, Paris, France

 2021 Philip Markus Memorial Lecture Speaker “Human type I interferonopathies”

Yanick Crow is a clinical scientist (MD-PhD) and Fellow of the Academy of Medical Sciences, working at the MRC Institute of Genetics and Molecular Medicine, Edinburgh, UK and the Institut Imagine, Paris, France. He has an interest in monogenic disorders associated with an up-regulation of type I interferons – a set of inborn errors of immunity resulting from abnormal sensing, inappropriate stimulation, or defective negative regulation of the type I interferon system. Understanding these so-called type I interferonopathies has the potential to provide insights into immunological homeostasis, mechanisms of self / non-self discrimination and viral immunity.

King’s College London

Franziska Denk is a Senior Lecturer at King’s College London, where she works on neuroimmune interactions and epigenetic mechanisms in the context of chronic pain. Her lab uses transgenic models and high-throughput molecular analyses, such as RNA-seq, on sorted cell populations (, @denk_lab).
Franziska studied Experimental Psychology at the University of Oxford and completed her DPhil there in 2009. She started her own research group in 2017 with the help of an MRC New Investigator Research Grant. Since then, she has also received funding from the European Union (IMI2), industry and several charities.
Franziska is passionate about data sharing (Denk, Nature, 2017) and interdisciplinary research in an open, positive research culture. She is co-Director of the Wellcome Trust funded PhD Training Scheme in Neuro-Immune Interactions in Health and Disease (

Trinity College Dublin

Padraic Fallon is Professor of Translational Immunology, School of Medicine, Trinity College Dublin, Ireland. Research involves the use of animal models, including mutant and transgenic strains, advances fundamental understanding of infection immunobiology and inflammatory disease processes. Translational mechanistic studies address innate and adaptive cellular responses in patient cohorts with inflammatory or infectious diseases.

Columbia University

Dr. Farber is the George H Humphreys, II Professor of Surgical Sciences (in Surgery) and Professor of Microbiology and Immunology at Columbia University. The focus of her research is on anti-viral immunity and human immunology. Dr. Farber’s laboratory identified tissue-resident memory T cells in the lung that mediate protective immunity to respiratory virus infection. These findings led her to establish a major initiative to study human tissue immunity and its development from infancy through adulthood in multiple mucosal and lymphoid tissues from organ donors of all ages. Dr. Farber’s research is supported by the NIH, Helmsley Charitable trust and Chan Zuckerberg initiative.

Monash University

Professor Mark Febbraio is a Senior Principal Research Fellow of the NHMRC, and the Head of the Cellular and Molecular Metabolism Laboratory within the Drug Discovery Program at Monash Institute of Pharmaceutical Sciences, Monash University Australia. His research is focussed on understanding mechanisms associated with exercise, obesity, type 2 diabetes and cancer and his aim is to develop novel drugs to treat lifestyle related diseases. He has authored over 270 papers and has over 40000 career citations. He has won several scientific prizes including the A K McIntyre Prize for significant contributions to Australian Physiological Science (1999), the Kellion Award for the Australian Diabetes Society (2017), The Eureka Scientific Prize (2020), The GSK Award for Research Excellence (2020) and The Endocrinology Society UK International Medallist (2021).

Umass Medical School

Dr. Fitzgerald is Professor and Vice Chair in the department of Medicine and the Director of the Program in Innate Immunity at Umass Medical School. She directs an internationally recognized laboratory focused on understanding the activation and resolution of the inflammatory response in both health and disease. The long-term goal of her work is to determine how inappropriate activation of innate immunity underlies the pathogenesis of infectious, inflammatory and autoimmune diseases in humans.

Dr. Fitzgerald is an elected member of the American Academy of Microbiology and the Royal Irish Academy. She has also received several awards including a MERIT award from the NIH, the Saint Patrick’s Day Medal, from the Irish Government and Science Foundation Ireland, the Milstein Award for Excellence in Interferon and Cytokine research (from the International Cytokine and Interferon Society), the Eli Lilly and Company Elanco Research Award (from the American Society of Microbiology) and the BD-Biosciences Investigator Award (from the American Association of Immunologists). She is ranked amongst the top 1% most Cited researchers for Immunology consistently since 2014 (Thompson Reuters, every year since 2014) and is currently President of the International Cytokine and Interferon Society.

University of Washington

Michael Gale, Jr. is Director of the University of Washington Center for Innate Immunity and Immune Disease. His research is focused on understanding the molecular basis of nonself recognition and regulation of innate immunity and inflammation in RNA virus infection.

Laurie H. Glimcher, MD is the President and CEO of the Dana-Farber Cancer Institute, Director of the Dana-Farber/Harvard Cancer Center and the Richard and Susan Smith Professor of Medicine at Harvard Medical School.

She is a Member of the National Academy of Sciences, the National Academy of Medicine and the American Philosophical Society, Fellow of the American Academy of Arts and Sciences and the former President of the American Association of Immunologists. She served on the Vice President’s Blue Ribbon panel. She currently serves on the Board of Directors of GlaxoSmithKline Pharmaceutical Corporation and Analog Devices, Inc.

Dr. Glimcher’s research identified key transcriptional regulators of protective immunity and the origin of pathophysiologic immune responses underlying autoimmune, infectious and malignant diseases.

Aside from her research efforts, Dr. Glimcher has been a staunch proponent of improved access to care, health policy, and medical education, while simultaneously serving as a pioneering mentor and role model for cancer research trainees and for all women in science.


Dr. Raphaela Goldbach-Mansky is the Chief of the Translational Autoinflammatory Diseases Section (TADS) in the Laboratory of Clinical Immunology and Microbiology (LCIM) at NIAID at the NIH. Dr. Goldbach-Mansky’s translational research program focuses on clinical and translational studies in children with early-onset autoinflammatory diseases. Her research applies an integrative approach to characterize the genetic and molecular causes of autoinflammatory diseases and to design targeted treatment studies to investigate the role of specific inflammatory pathways in the pathogenesis of autoinflammatory diseases with the ultimate goal to improve disease outcomes. Her studies in patients with NOMID and DIRA established targeted treatments with IL-1 inhibitors as standard of care and led to FDA approval of anakinra for NOMID in 2012 and anakinra and rilonacept in DIRA in 2020. Her recent translational and interventional studies in patients with CANDLE, SAVI and other autoinflammatory diseases with chronic IFN signatures focus on understanding the pathogenic role for Type I Interferons in the disease pathogenesis and on the role of IL-18 in predisposing to the development of macrophage activation syndrome. Dr. Goldbach-Mansky established the Translational autoinflammatory research network (TARN) to promote translational research in patients with rare autoinflammatory diseases.

University of Glasgow

Professor Gerry Graham BSc, PhD, FRSE, FMedSci
Gerry Graham is Gardiner Chair of Immunology and Head of the Chemokine Research Group ( at the University of Glasgow and is also interim Director of the Institute of Infection, Immunity and Inflammation. He has worked in the field of chemokine biology for over 30 years and has been responsible for many of the seminal discoveries in this area. He has two major interests in terms of chemokine research: firstly, his group are amongst the world leaders in the study of atypical chemokine receptors and their role in the regulation of chemokine function; secondly, he is using complex genomic approaches to try to understand, in more detail, the orchestration of the chemokine-driven inflammatory response. Work in Gerry’s lab is supported by a Medical Research Council Programme Grant and by a Wellcome Trust Senior Investigator Award. He is a recipient of a Wolfson Royal Society Merit Award and has been elected Fellow of the Royal Society of Edinburgh and the Academy of Medical Sciences. He has served on a number of grants panels, including the Leukaemia Research Fund Medical and Scientific Advisory Panel. He also spent over four years as a member of the Medical Research Council Infections and Immunity Board and is currently the Chair of the Wellcome Trust Expert Review Group in the Immune System in Health and Disease. He publishes regularly in prominent international journals and is frequently invited to major international scientific meetings.

University of Melbourne

John Hamilton has made significant molecular and translational contributions to the field of inflammation. He has shown how colony-stimulating factors (CSFs) control macrophage lineage numbers and function in inflammation, mainly in the contexts of arthritic disease and inflammation-associated pain. He discovered the role of CSFs in inflammation, pioneered cell signalling studies for the CSFs, and progressed the biology of the CSFs to encourage and facilitate several successful international clinical trials with antagonists to the CSFs, for example, in arthritis and cancer.

University of Alabama at Birmingham

Imperial College London

James is a senior lecturer at the National Heart and Lung Institute at Imperial College London. His team have a long standing interest in cytokine mediated regulation of CD4 T cell responses, and how there are altered in early life compared to adulthood. Recently this work has focused on using both mouse models and human samples to explore the balance between STAT3 and STAT5 signalling cytokines and how this determines differences in antibody production.

Cardiff University

Ian Humphreys is a Wellcome Trust Senior Research Fellow, Professor of Viral Pathogenesis and Director of the Systems Immunity University Research Institute at Cardiff University, UK. The laboratory studies mechanisms that regulate antiviral immune responses and seeks to understand how these processes can restrict viral pathogenesis but also, in certain contexts, facilitate virus persistence and dissemination.

University of Pennsylvania

Dr. Hunter’s laboratory focuses on the events that lead to the development of protective immunity as well as to limit T cell mediated pathology during parasitic infections and the role of cytokines in these processes. We are able to utilize different combinations of transgenic parasites to study how cytokines such as IFN-gamma, IL-2, IL-10, IL-12, IL-18 and IL-27 affect resistance to infection. Dr. Hunter obtained his Ph.D. from the University of Glasgow and is a Professor at the University of Pennsylvania and is the President elect of the ICIS.

Lancaster University

Dr Lucy Jackson-Jones is a Lecturer in Biomedicine at Lancaster University. The Jackson-Jones laboratory investigates local immune responses that occur within the body cavities. We use mouse models and patient samples to reveal the interactions that occur between immune cells, stromal cells and their secreted products within serous fluid and fat associated lymphoid clusters in the context of inflammation.

Hudson Institute of Medical Research

Professor Brendan Jenkins is Deputy Director of the Centre for Innate Immunity and Infectious Diseases at the Hudson Institute of Medical Research, Australia. His research interest is to define the roles that innate immune regulators, namely pattern recognition receptors and IL-6 family cytokines, play in the pathogenesis of inflammation-associated cancers, including those of the stomach, pancreas and lung. His research programs incorporate long standing collaborations with basic scientific researchers and clinicians both nationwide and overseas, with a view to translate his preclinical findings into the clinic.

University of Bristol
Dr Gareth Jones is a Senior Lecturer in Immunology at the School of Cellular and Molecular Medicine, University of Bristol, UK. His research investigates mechanisms by which IL-6 family cytokines regulate tissue inflammation and damage, with an interest in the negative control of inflammation to restore tissue homeostasis. This has recently been applied to understanding the development and maintenance of ectopic lymphoid-like structures (also called tertiary lymphoid structures) in autoimmunity and cancer. Through collaboration with basic scientists, clinicians and industry, his research spans fundamental and early clinical studies with a view to clinical translation.

St. Jude Children’s Research Hospital

Thirumala-Devi Kanneganti is a Member and Vice Chair of the Immunology Department at St. Jude Children’s Research Hospital, and she is the Rose Marie Thomas Endowed Chair. She is a founding member of the inflammasome field, and her lab continues to make critical contributions to this research discipline. She also identified master regulators of inflammasome activation and the cell death pathways pyroptosis, apoptosis, and necroptosis, leading her to pioneer the concept of PANoptosis and describe its implications in health and disease.


Dr. Yuka Kanno was born in Japan and attended Tohoku University School of Medicine, received MD and PhD in medical science. After completing her residency in internal medicine, she moved to the US and trained in molecular biology at National Institutes of Health. She has been working at National Institute of Arthritis and Musculoskeletal and Skin Diseases since 2003 as Staff Scientist, engaging in basic and translational research to study immune cells. She aims to understand cell-type specific genome organization and gene transcription, and how extracellular signals influence epigenetic information built in chromatin of various immune cells.

University of Bristol

Golam Khandaker is Professor of Psychiatry and Head of the Immunopsychiatry and Experimental Medicine Programme at the MRC Integrative Epidemiology Unit, University of Bristol. His research focuses on identifying and validating novel immunological mechanisms and potential treatment targets for depression and psychosis using population-based data, genetic analysis, and proof-of-concept experimental medicine trials of novel immunotherapies in patients with depression and psychosis. Using prospective cohort and Mendelian randomization designs, Golam has reported evidence for potential causal role for IL-6 in depression and psychosis. This work has led to two proof-of-concept RCTs of the anti-IL-6R monoclonal antibody tocilizumab for depression (Insight study) and psychosis (PIMS trial) funded by the Wellcome Trust and MRC respectively.

Medical University Innsbruck, Institute of Physiology

Michaela Kress is a physician scientist and full professor at the Department of Physiology and Biomedical Physics Medical University of Innsbruck in Austria. She served as President of the Austrian Neuroscience Association, member of the Scientific Program Committee of several congresses of the international (IASP) and European (EFIC) pain societies. She coordinated the ncRNAPain research consortium funded by the European Commission. She teaches medical students and supervises PhD students in MSCA- and FWF funded programs. Her research focus is on neuroimmune interactions in the nervous system and their hub regulators in the pain pathway. These are explored by integrating multiple methodological approaches ranging from behavior phenotyping to expression analysis and electrophysiological recordings from peripheral nerve and from neuronal networks in the brain. In particular, non-coding RNAs, the proinflammatory cytokine interleukin-6 and its signal transducer Il-6/gp130 are explored and novel models for pain disorders developed with a recent focus on human model systems.

FAU European Grant Gerhard Krönke Life sience 9. Dezember 2014

University of Erlangen

After graduating from the Medical University of Vienna in 2002, Gerhard Krönke worked as postdoctoral researcher at the Medical University of Vienna (2002-2004) and the University of Virginia, Charlottesville (2004-2006). From 2006-2015 he conducted his clinical training in Internal Medicine and subsequently in Rheumatology at the University Hospital Erlangen, where he is currently working as Senior Physician at the Department of Internal Medicine 3 since 2012. In 2016, he was appointed Professor of Translational Immunology at the University of Erlangen-Nürnberg. His research focuses on cellular, molecular and metabolic pathways involved in the maintenance and break of immunological self-tolerance as well as the onset and resolution of inflammation. In particular, he is trying to understand the mechanisms and events leading to the development of inflammatory autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematodes and to develop novel strategies for their diagnosis and treatment. In 2014 he received an ERC Starting grant and is currently acting as the spokesperson of the DFG research unit FOR2886 “PANDORA” (Pathways triggering AutoimmuNity and Defining Onset of early Rheumatoid Arthritis).

Brigham and Women’s Hospital/Harvard Medical School

Dr. Vijay Kuchroo is the Samuel L. Wasserstrom Professor of Neurology at Harvard Medical School, Senior Scientist at Brigham and Women’s Hospital, Co-Director of the Center for Infection and Immunity, Brigham Research Institutes, an Institute Member of the Broad Institute, a collaborator in the Klarman Cell Observatory project that focuses on T cell differentiation, and Director of the Evergrande Center for Immunologic Diseases at Harvard Medical School and Brigham and Women’s Hospital.

His major research interests include autoimmune diseases, particularly the role of co-stimulation, the genetic basis of experimental autoimmune encephalomyelitis and multiple sclerosis, and cell surface molecules and regulatory factors that regulate induction of T cell tolerance and dysfunction.

University College London

Helen Lachmann is a Professor of Medicine at University College London & Clinical Service Lead for Immunity & Rare Diseases Division, Royal Free Hospital London

Having trained in medicine at the University of Cambridge & at University College London, she started her research at the UK National Amyloidosis Centre in 1999. She has published widely & her main scientific interests are focused on the genetics & management of the systemic autoinflammatory diseases & characterization & treatment of acquired & hereditary systemic amyloidosis.

Imperial College

Clare Lloyd is Professor of Respiratory Immunology, Head of the Division of Respiratory Sciences at the National Heart and Lung Institute, and Vice Dean for Institutional Affairs in the Faculty of Medicine at Imperial College, London. The Lloyd lab explores the interactions between resident lung cells and immune cells during development and resolution of pulmonary inflammation. The lab uses a mixture of in vivo mouse models and in vitro culture systems using cells from patients to investigate the mechanisms underlying the pulmonary immune response to inhaled allergens and pathogens. The current focus is predominantly how the genetic background of an individual and the external environment influences epithelial-immune interactions, particularly with respect to infection history and development of allergic immune responses in early life.

University of  Manchester

Andrew MacDonald completed his PhD studying immunity to parasitic worms (helminths) at the University of Edinburgh in 1998. After several years in the U.S., first at Cornell University and then at the University of Pennsylvania, he returned to the UK in 2002 to the University of Edinburgh where he established his lab through successive MRC Career Development and Senior Fellowships at the Institute of Immunology and Infection Research. In January 2013 he took up the position of Professor of Immunology at the Manchester Collaborative Centre for Inflammation Research, within the Lydia Becker Institute of Immunology and Inflammation at the University of Manchester.

Research in his lab addresses some outstanding fundamental questions about activation and modulation of cellular immunity, with a particular focus on dendritic cells and macrophages, and T cell activation by antigen presenting cells during inflammation caused by helminths or allergens. His research aims to better understand how immunity and inflammation is promoted or regulated during disease, with emphasis on murine mechanistic studies in vivo during helminth infection or in allergic airway inflammation, complemented by analysis of ex vivo patient samples. Current projects include determining the importance of different dendritic cell and macrophage subsets during pulmonary and intestinal type 2 inflammation, and the role of the tissue environment, metabolism and the host microbiota in these processes.

Newcastle University

Derek Mann is a molecular biologist who for the past 3 decades has focussed his work on the biology of liver disease and translation of fundamental discoveries to clinical investigations. He is best known for his discoveries on the epigenetic and transcriptional control of fibrosis, in particular the role of the NF-kB family of transcription factors. More recently he has developed projects that are illuminating the role of neutrophils in ageing and cancer. He is currently Professor of Hepatology at Newcastle University where he leads the Newcastle Fibrosis Research Group. In addition he is a founding scientist, director and CSO of the spinout company FibroFind which is a CRO working with many of the major pharmaceutical companies to develop anti-fibrotic molecules towards clinical use.

University of Glasgow

Professor Iain McInnes is Vice Principal and Head of the College of Medical, Veterinary and Life Sciences, Muirhead Chair of Medicine and Versus Arthritis Professor of Rheumatology at the University of Glasgow.

A global leader in the field of arthritis research, over two decades, Professor McInnes has led numerous clinical trials and pathogenesis investigation programmes in inflammatory arthritis at an international level. His work has focused on the biology of inflammatory cytokines in arthritis and extended to other inflammatory diseases. More recently, he has worked on the mechanisms of co-morbidities in chronic diseases. He has also pioneered the area of precision medicine in inflammatory arthritis.

For the last five years, Professor McInnes has served as Director of the Arthritis Research UK Centre of Excellence for Rheumatoid Arthritis, renewed as the UK Centre for Inflammatory Arthritis through to 2024. He is Chief Investigator of the IMID-Bio-UK meta-consortium leading the UK effort to discover precision medicine tractable biomarkers for application in immune diseases. He is immediate past chairman of the FOREUM (Foundation for European Rheumatology Research) Scientific Committee, leads the European Roadmap programme that is defining the research agenda for European rheumatology for the next decade, and is President of EULAR (European Alliance of Associations for Rheumatology), the largest global transnational rheumatology organisation.

Professor McInnes is a Fellow of the Royal Society of Edinburgh and the Academy of Medical Sciences. He is the recipient of several prestigious prizes in recognition of his work, including the Sir James Black Medal of the Royal Society of Edinburgh in 2017, the Heberden Medal of the British Society for Rheumatology in 2018, and the Carol-Nachman Prize for Rheumatology, Germany (the highest international award in rheumatology) in 2019. He was awarded a CBE for services to medicine by Her Majesty the Queen in 2019.

University of Dundee

Ignacio Moraga is a Principal Investigator in the Cell Signalling and Immunology Department at University of Dundee, UK. The Moraga lab studies how cytokines regulate immune cell fate decisions. The objective is to gain key insights into the molecular mechanisms that underlie cytokine functional diversity. Fundamental to the lab program is the use of protein engineering to manipulate cytokine immuno-modulatory activities with the ultimate goal to inform new therapies for immunomodulation.

Trinity College Dublin

Luke O’Neill is Professor of Biochemistry in the School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute at Trinity College Dublin, Ireland. He is a world expert on innate immunity and inflammation. His main research interests include Toll-like receptors, Inflammasomes and Immunometabolism. Professor O’Neill is co-founder of Sitryx, which aims to develop new medicines that target immunometabolism for inflammatory diseases.

Imperial College London


Peter Openshaw is a respiratory physician and mucosal immunologist. He has worked on common cold viruses (RSV and influenza) since the mid-1980s and is/has been a government policy advisor (SAGE, NERVTAG, SPI etc.). He is the Director of HIC-Vac, an international consortium that promotes the use of human volunteer infection to accelerate vaccine development for pathogens of high global impact. He is a former President of the British Society for Immunology and a co-Lead on ISARIC4C study of COVID-19.



John O’Shea, MD joined the NIH in 1981, and was appointed Scientific Director of NIAMS in 2005. His interest is cytokine signaling and the role of Jaks and Stats in immunoregulation, lymphocyte differentiation, transcriptional and epigenomic regulation. His lab cloned JAK3, demonstrated its role in immunodeficiency and collaborated with industry partners in the development of therapeutic JAK inhibitors. He has received many awards, including: the Howley Prize, the Ross Prize, the Milstein Award, and the AAI-Steinward Award. He was elected to the American Association of Physicians, National Academy of Medicine and is a Master in the American College of Rheumatology.

Queen Mary University of London

Fiona Powrie, Wellcome Governor

Kennedy Institute

Professor Fiona Powrie is Director of the Kennedy Institute of Rheumatology, University of Oxford, a Fellow of the Royal Society and a Governor of the Wellcome Trust. She gained a PhD in immunology at the University of Oxford and then moved to the DNAX Research Institute in Palo Alto, before returning to Oxford in 1996 as a Wellcome Trust Senior Research Associate. Prior to her appointment to the Kennedy Institute, Fiona Powrie was the Sidney Truelove Professor of Gastroenterology and Head of the Translational Gastroenterology Unit, Oxford (2009- 2014). Her research examines the relationship between the intestinal microbiome and the host immune system and how this mutualistic relationship breaks down in inflammatory bowel disease, arthritis and cancer. She has received numerous prestigious prizes and awards, including the Louis Jeantet Prize for Medicine in 2012 and was elected an international member of the National Academy of Sciences in 2020.

Fred Hutchinson Cancer Research Center

The Prlic laboratory primarily studies T cell and innate-like T cell responses in mucosal tissues, with a particular interest in understanding how these cells function in different inflammatory environments, including infections and cancer. By defining the functional plasticity and functional potential of T cells in health and a range of different disease states, we aim to understand how we can manipulate these cells to our advantage. Our goal is to understand the molecular basis of cell activation and differentiation to learn how to manipulate the cells for therapeutic purposes and ultimately improve human health.


Professor with tenure, laboratory of Human Genetics of Infectious Diseases (HGID), INSERM1163, Imagine Institute, University of Paris, Paris, France and Adjunct Faculty Member, HGID Lab, The Rockefeller University, New York City, NY, USA. Group Leader: Human genetic determinism of fungal diseases

Yale University

University of Kiel

Stefan Rose-John is full Professor of Biochemistry and Director of the Institute for Biochemistry at the University of Kiel Medical School in Kiel, Germany. His research is focused on the molecular biology of cytokines. He has established the paradigm of Interleukin-6 trans-signaling via soluble Interleukin-6 receptor. He has found that Interleukin-6 trans-signaling is mainly pro-inflammatory whereas classic Interleukin-6 signaling via the membrane-bound Interleukin-6 receptor is rather protective. He has developed a specific inhibitor of Interleukin-6 trans-signaling, which does not interfere with classic Interleukin-6 signaling. This inhibitor, named Olamkicept has now finished phase II clinical trials for the treatment of autoimmune diseases and is on its way to phase III clinical trials.

Institute of Biochemistry and Molecular Biology II

1999-2002 IPK Gatersleben, Germany
2002-2010 Biochemical Institute, University Kiel, Germany
since 2010 Institute of Biochemistry and Molecular Biology II, University Düsseldorf, Germany

Korea Advanced Institute of Science and Technology

Eui-Cheol Shin received his M.D. (1996) and Ph.D. (2001) from Yonsei University College of Medicine, Seoul, Republic of Korea, and his postdoctoral training from NIDDK, National Institutes of Health, Bethesda, Maryland, USA. Then he joined Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, Republic of Korea in 2007, where he is currently a professor. KAIST. His laboratory, the Laboratory of Immunology and Infectious Diseases, performs researches on T cell responses in human viral disease and cancer. In particular, they currently focuses on ‘T cell-mediated immunopathogenesis’, ‘senescence of T cells’, ‘reinvigoration of exhausted T cells’, ‘human immune monitoring’ and ‘immune responses in SARS-CoV-2 infection and COVID-19’.

Johns Hopkins University

Dr. Jamie Spangler earned a Bachelor of Science degree in Biomedical Engineering at Johns Hopkins University and went on to earn a Ph.D. in Biological Engineering at MIT. After completing a postdoctoral fellowship at Stanford University School of Medicine, Dr. Spangler launched her independent research group at Johns Hopkins University in July 2017, jointly between the departments of Biomedical Engineering and Chemical & Biomolecular Engineering. Her lab, located in the Translational Tissue Engineering Center at the School of Medicine, applies structural and mechanistic insights to re-engineer existing proteins and design new proteins that therapeutically modulate the immune response. In particular, her group is interested in engineering immune molecules such as cytokines, growth factors, and antibodies for targeted treatment of diseases such as cancer and autoimmune disorders.

University of Central Florida

Tara Strutt is an Assistant Professor within the Immunity and Pathogenesis Division of the College of Medicine Burnett School of Biomedical Sciences at the University of Central Florida in Orlando, FL USA and is an affiliate faculty member of the UCF NanoScience Technology Center. She earned her Ph.D. in Immunology from the University of Saskatchewan in Canada and did her postdoctoral studies at the Trudeau Institute in NY prior to joining the Faculty at the University of Massachusetts Medical School in MA. Her studies have uncovered novel protective functions mediated by memory CD4 T cells during respiratory virus infection. Her research is centered on understanding how the how the adaptive immune system regulates innate inflammatory responses in the respiratory tract.

Wellcome Sanger Institute

Sarah Teichmann is interested in global principles of regulation of gene expression and protein complexes, with a focus on immunity. Sarah did her PhD at the MRC Laboratory of Molecular Biology, Cambridge, UK and was a Beit Memorial Fellow at University College London. She started her group at the MRC Laboratory of Molecular Biology in 2001, discovering stereotypical pathways of assembly and evolution of protein complexes during this time. In 2013, she moved to the Wellcome Genome Campus in Hinxton/Cambridge, jointly with the EMBL-European Bioinformatics Institute and the Wellcome Sanger Institute (WSI). In February 2016 she became Head of the Cellular Genetics Programme at the WSI and co-founded the Human Cell Atlas international initiative which she continues to lead. Sarah was elected a member of EMBO in 2012, a fellow of the Academy of Medical Sciences in 2015 and a fellow of the Royal Society in 2020.

Monash University

Professor Tony Tiganis currently heads the Monash Biomedicine Discovery Institute’s Metabolism, Diabetes and Obesity Program. His general research interest is in understanding cellular signalling networks and tissue crosstalk in human disease. He was educated at The University of Melbourne and completed his PhD with Prof. Bruce E. Kemp, St Vincent’s Institute, Melbourne, before pursuing post-doctoral training with Prof. Nicholas K. Tonks, Cold Spring Harbor Laboratory, NY. He then established an independent laboratory at Monash University in 2000 and in recent years held a joint appointment at the Peter MacCallum Cancer Centre. Professor Tiganis also holds an adjunct position with the Yale School of Medicine.

Professor Tiganis’ laboratories are focused on understanding the molecular mechanisms contributing to the development of obesity and diabetes and determining how obesity and metabolism affect tumour cells and the immune system to promote the development of cancer, taking an integrative encompassing the fields of metabolism, immunology and cancer to address fundamental questions in biology and disease.

Monash University

Professor Stephen Turner is Head of the Department of Microbiology, Monash University and the President of the Australian and New Zealand Society for Immunology. He was awarded his PhD in Viral Immunology from Monash University in 1997. He trained with Nobel Laureate, Professor Peter Doherty (St Jude Children’s Research Hospital, USA) to work on influenza virus-specific T cell immunity before returning to the University of Melbourne in 2002, to establish his own research group. His research interests utilize a combination of structural biology, genomics, systems biology, recombinant viral technology and cellular immunology to examine molecular factors that impact T cell responses to virus infection.

University of Oxford

Holm Uhlig is a Professor of Paediatric Gastroenterology in the Translational Gastroenterology Unit, University of Oxford and Children’s Hospital Oxford. After Medical training in Leipzig, he received his DPhil in Oxford. He specialised subsequently in Paediatric Gastroenterology in Germany. After returning to Oxford in 2010, Holm’s research is focused on genetics and immunology of inflammatory bowel disease. Holm sees patients with rare forms of inflammatory bowel disease such as Primary Immunodeficiencies that can present with Crohn’s disease and tries to understand the mechanisms that cause intestinal inflammation.

The Centre for Arthritis and Rheumatic Disease

Douglas Veale MD, FRCPI, FRCP(Lon) is Professor of Medicine, Director of Translational Research, University College of Dublin. He is a consultant rheumatologist at St Vincent’s University Hospital, Dublin, Ireland and Lead of the EULAR Centre of Excellence for Arthritis and Rheumatic Disease. He is a fellow at the Conway Institute for Biomedical and Biomolecular Research at the University College Dublin in Dublin, Ireland. He is a fellow of both the Royal College of Physicians in Ireland and the Royal College of Physicians, London. Prof. Veale’s primary research interests include inflammatory arthritis, novel biopharmaceutical therapies, and mechanisms of disease in rheumatoid and psoriatic arthritis. He has authored more than 400 peer-reviewed articles, reviews, and book chapters.

University of Southampton

Professor Tom Wilkinson is Professor of Respiratory Medicine at the University of Southampton, Faculty of Medicine and Honorary Consultant at University Hospitals Southampton. He trained at the University of Cambridge and Barts and the London School of Medicine and completed his PhD at UCL studying disease mechanisms driving Infective Exacerbations of COPD. He is lead of the Southampton COPD research group, and Airways disease research theme lead for the NIHR Southampton Biomedical Research Centre. His research seeks to improve understanding of the mechanisms which drive susceptibility to respiratory infections and exacerbations in patients with chronic lung disease, and to develop new vaccines and therapies to impact on these. He is leading a number of studies developing new treatments for COVID-19.

Billy and Audrey L. Wilder Professor in Tumor Immunotherapy; Associate Chair and Professor, Department of Immuno-Oncology; Co-leader, Cancer Immunotherapeutics Program, City of Hope Comprehensive Cancer Center, Duarte, CA USA
Dr. Yu’s laboratory was the first to validate STAT3, a critical regulator of tumor cell survival and proliferation, as a molecular target for cancer therapy in animal models. Yu’s team also unraveled a critical role of STAT3 in tumor angiogenesis and tumor immune evasion.
Research Focus

Rockefeller University

I’m a pediatrician trained in Shanghai. I focus my research on inborn errors of immunity (IEIs) in patients with severe viral infections and the underlying immunological mechanisms.

Toggle Content